OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptiNose prioritizes XHANCE launch for sinusitis, eyes growth opportunities

OptiNose is focusing on profitability and preparing for the launch of XHANCE for chronic sinusitis, anticipating improved financial performance in 2023.
The company's strategic initiatives include exploring commercial partnerships, optimizing expenses, and evaluating potential sale options, indicating a proactive approach to growth.
While facing challenges in revenue generation and prescription volumes, OptiNose is leveraging strengths in financial stability, market reach, and growth opportunities.

OptiNose reports steady Q1 performance amidst revenue challenges and growth opportunities

OptiNose's Q1 2023 performance showed steady prescription demand and a strategic focus on profitability and growth.
While facing challenges like revenue decline and sales force impact, the company is poised for opportunities in market expansion and successful product launches.
Overall, OptiNose remains optimistic about meeting expectations and future approval, positioning itself for continued success in the pharmaceutical market.

OptiNose reports steady Q2 performance, eyes growth with new indications

OptiNose's Q2 2023 performance showed stable prescription demand and a strategic focus on the potential launch of a chronic sinusitis treatment in 2024.
While facing challenges like slightly lower net revenue and upcoming operating expenses, the company is well-positioned for growth opportunities.
With raised revenue guidance, a clear operating strategy, and ongoing FDA review, OptiNose is poised for potential revenue expansion and market growth.

OptiNose reports stable Q3 revenue, eyes growth through XHANCE launch

OptiNose's Q3 2023 performance showed stability in revenue and improved cost efficiency.
While facing challenges in prescription numbers, the company is strategically positioned for growth.
Opportunities lie in potential market expansion through new indications and partnerships.

OptiNose reports strategic growth in Q4 2023, eyes XHANCE approval

OptiNose's performance in Q4 2023 showcased progress in key areas, with a strategic focus on growth and efficiency. The company's financials reflected a reduction in expenses and a stable product demand, positioning it well for potential XHANCE approval and revenue expansion.

OptiNose reports strong Q1 performance and outlines growth strategies

OptiNose's Q1 2024 performance reflects growth in XHANCE net revenue and a strengthened financial position.
The company's strategic focus on chronic sinusitis launch and improved base business fundamentals bode well for future growth.
Opportunities lie in expanding sales efforts, international partnerships, and new product development for sustained value creation.

OptiNose reports Q3 revenue growth, adjusts full-year guidance

OptiNose's Q3 performance showed revenue growth and strategic adjustments.
While challenges like conservative guidance were raised, opportunities for growth exist.
Management's focus on execution and communication bodes well for future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The primary and secondary endpoints were met in phase 3 clinical trial.

OptiNose: Underappreciated Potential

OptiNose, Inc. (OPTN) CEO Peter Miller on Q4 2021 Results - Earnings Call Transcript

Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million

Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Optinose Inc (NASDAQ: OPTN) has announced positive data from the ReOpen1 Phase 3 trial of Xhance (fluticasone propionate) Exhalation Delivery System in chronic sinusitis. The trial met both of its co-primary endpoints - First, a composite symptom score (comprising nasal congestion,.

Optinose's XHANCE Meets Primary Endpoints In Chronic Sinusitis Trial

XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis

Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis

Conference Call and Webcast to be held March 8, 2021 at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Lazydays

Motorcar Parts of America

Quotient

Sunopta

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors.

Optinose Announces Appointment of Two New Members to Board of Directors

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Piper Sandler 33rd Annual Virtual Healthcare Conference scheduled for November 29 through December, 2, 2021.

Optinose to Present at the Piper Sandler Virtual Healthcare Conference

OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.

OptiNose (OPTN) Sees Hammer Chart Pattern: Time to Buy?

The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 44.2% in 4 Weeks, Here's Why the Trend Might Reverse for OptiNose (OPTN)

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced underwritten public offering of 28,750,000 shares of its common stock at a public offering price of $1.60 per share, including the exercise in full by the underwriters of their option to purchase up to 3,750,000 additional shares of common stock. The gross proceeds of the offering to Optinose are $46.0 million, before deducting underwriting discounts and before offering expenses.

Optinose Announces Closing of $46.0 Million Public Offering of Common Stock

OptiNose, Inc. (OPTN) CEO Peter Miller on Q3 2021 Results - Earnings Call Transcript

YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.60 per share, for gross proceeds of $40.0 million to Optinose, before deducting underwriting discounts and before offering expenses. All shares of common stock in the offering are being offered by Optinose. In addition, Optinose has granted the underwriters an option for a period of 30 days to purchase up to an additional 3,750,000 shares at the public offering price, less the underwriting discount. The offering is expected to close on or about November 18, 2021, subject to the satisfaction of customary closing conditions.

Optinose Announces Pricing of Public Offering of Common Stock

The stock price of OptiNose Inc (NASDAQ: OPTN) fell by over 25% pre-market today. This is why it happened.

OptiNose (OPTN) Stock: Why The Price Substantially Fell Today

ENT and allergy-focused company Optinose Inc (NASDAQ: OPTN) posted Q3 Xhance (fluticasone propionate) sales of $21.8 million, +41% Y/Y, missing the consensus of $23.48 million. The Company held cash and cash equivalents of $84.2 million as of September 30, 2021.

See Why Optinose Shares Plunged To 52-Week Low Today

OptiNose (OPTN) delivered earnings and revenue surprises of 13.51% and -8.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q3 Loss, Lags Revenue Estimates

YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares of common stock to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares to be offered at the public offering price, less the underwriting discount. The public offering price has not yet been determined. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Optinose Announces Proposed Public Offering of Common Stock

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020

Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time

Optinose Announces Reporting Date for Third Quarter 2021 Financial Results

Will OptiNose (OPTN) Report Negative Q3 Earnings? What You Should Know

Company Expects Top-Line Results in Second Quarter 2022

Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis

YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8:40 a.m. ET.

Optinose to Present at the Cantor Virtual Global Healthcare Conference

According to OptiNose's management, in 2021, the company's revenue will be at least $80 million, which is 62.9% more than in 2020. The company's gross margin is around 87%, well above the pharmaceutical industry average.

News for OptiNose Stock (OPTN)